BRPI1107312B1 - Composto de acil-hidrazona - Google Patents
Composto de acil-hidrazona Download PDFInfo
- Publication number
- BRPI1107312B1 BRPI1107312B1 BRPI1107312-8A BRPI1107312A BRPI1107312B1 BR PI1107312 B1 BRPI1107312 B1 BR PI1107312B1 BR PI1107312 A BRPI1107312 A BR PI1107312A BR PI1107312 B1 BRPI1107312 B1 BR PI1107312B1
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- drugs
- och3
- cells
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
- C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/107—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with two aryl or substituted aryl radicals attached in positions 2 and 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/36—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI1107312-8A BRPI1107312B1 (pt) | 2011-11-25 | 2011-11-25 | Composto de acil-hidrazona |
| BR112014012582A BR112014012582A2 (pt) | 2011-11-25 | 2012-11-26 | compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos |
| EP12851308.2A EP2784061B1 (en) | 2011-11-25 | 2012-11-26 | Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof |
| KR1020147017498A KR102189562B1 (ko) | 2011-11-25 | 2012-11-26 | 아실-하이드라존 및 옥사디아졸 화합물, 이를 포함하는 약학 조성물 및 이의 용도 |
| JP2014542646A JP2015504432A (ja) | 2011-11-25 | 2012-11-26 | アシル−ヒドラゾンおよびオキサジアゾール化合物、これらを含有する医薬組成物およびその使用 |
| CN201280063518.9A CN104159887A (zh) | 2011-11-25 | 2012-11-26 | 酰基-腙和噁二唑化合物、含有它们的药物组合物及其用途 |
| CA2869807A CA2869807C (en) | 2011-11-25 | 2012-11-26 | Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof |
| US14/360,279 US20150191445A1 (en) | 2011-11-25 | 2012-11-26 | Acyl-hydrazone and oxadiazole compounds, pharmaceutical compositions containing the same and uses thereof |
| RU2014125519A RU2664327C2 (ru) | 2011-11-25 | 2012-11-26 | Ацил-гидразоновые и оксадиазоловые соединения, фармацевтические композиции, содержащие их, и их применение |
| PCT/BR2012/000480 WO2013075199A1 (pt) | 2011-11-25 | 2012-11-26 | "compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI1107312-8A BRPI1107312B1 (pt) | 2011-11-25 | 2011-11-25 | Composto de acil-hidrazona |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1107312A2 BRPI1107312A2 (pt) | 2016-09-20 |
| BRPI1107312B1 true BRPI1107312B1 (pt) | 2021-09-08 |
Family
ID=48468927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1107312-8A BRPI1107312B1 (pt) | 2011-11-25 | 2011-11-25 | Composto de acil-hidrazona |
| BR112014012582A BR112014012582A2 (pt) | 2011-11-25 | 2012-11-26 | compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112014012582A BR112014012582A2 (pt) | 2011-11-25 | 2012-11-26 | compostos acil-hidrazonas e oxadiazóis, composições farmacêuticas compreendendo os mesmos e seus usos |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20150191445A1 (enExample) |
| EP (1) | EP2784061B1 (enExample) |
| JP (1) | JP2015504432A (enExample) |
| KR (1) | KR102189562B1 (enExample) |
| CN (1) | CN104159887A (enExample) |
| BR (2) | BRPI1107312B1 (enExample) |
| CA (1) | CA2869807C (enExample) |
| RU (1) | RU2664327C2 (enExample) |
| WO (1) | WO2013075199A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101719541B1 (ko) | 2015-08-13 | 2017-03-24 | 연세대학교 산학협력단 | 항암용 약학 조성물 및 ano1 활성억제제 |
| KR20170141542A (ko) * | 2016-06-15 | 2017-12-26 | 국립암센터 | 위암을 예방 및 치료하는 rhoa 억제제의 약학적 조성물 |
| CN110498809B (zh) * | 2018-05-17 | 2022-04-05 | 香港科技大学深圳研究院 | 基于酰腙配体类的有机硼化合物及其制备方法和应用 |
| KR102131331B1 (ko) | 2018-09-19 | 2020-07-07 | 연세대학교 산학협력단 | 항암용 신규 약학 조성물 및 ano1 활성억제제 |
| CN113336729B (zh) * | 2021-05-31 | 2022-05-27 | 四川大学华西医院 | 硝呋齐特类衍生物及其制备方法和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60105621A (ja) * | 1983-11-14 | 1985-06-11 | Agency Of Ind Science & Technol | 細胞の分化誘導作用を有する生理活性物質およびその製法 |
| IL94389A0 (en) * | 1989-06-01 | 1991-03-10 | Health Research Inc | Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and method of using same for diagnosis and treatment |
| US5372808A (en) * | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
| US6197806B1 (en) * | 1995-12-20 | 2001-03-06 | Nippon Zoki Pharmaceutical Co., Ltd. | Eliminating agent for activated oxygen and free radicals |
| CA2400996A1 (en) | 2002-09-03 | 2004-03-03 | Lisa Mckerracher | 1,4-substituted cyclohexane derivatives |
| KR101155883B1 (ko) | 2003-12-23 | 2012-06-20 | 아제닉스 유에스에이 인코포레이티드 | 사이클린 의존적 키나제 저해제, 그 조성물 및 그의 용도 |
| DE102004010207A1 (de) | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
| WO2005097763A2 (en) * | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as ppar delta |
| AR052559A1 (es) | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| WO2006101937A1 (en) | 2005-03-18 | 2006-09-28 | Janssen Pharmaceutica N.V. | Acylhydrazones as kinase modulators |
| CN1824657A (zh) * | 2006-04-05 | 2006-08-30 | 贵州大学 | 3－取代－2－芳基取代－5－(3,4,5－三烷氧基苯基)－1,3,4－噁二唑衍生物及制备方法和用途 |
| US20110189306A1 (en) * | 2010-01-13 | 2011-08-04 | Norbert Kartner | COMPOUNDS, COMPOSITIONS AND TREATMENTS FOR V-ATPase RELATED DISEASES |
-
2011
- 2011-11-25 BR BRPI1107312-8A patent/BRPI1107312B1/pt not_active IP Right Cessation
-
2012
- 2012-11-26 EP EP12851308.2A patent/EP2784061B1/en active Active
- 2012-11-26 WO PCT/BR2012/000480 patent/WO2013075199A1/pt not_active Ceased
- 2012-11-26 JP JP2014542646A patent/JP2015504432A/ja active Pending
- 2012-11-26 RU RU2014125519A patent/RU2664327C2/ru active
- 2012-11-26 KR KR1020147017498A patent/KR102189562B1/ko active Active
- 2012-11-26 CA CA2869807A patent/CA2869807C/en active Active
- 2012-11-26 US US14/360,279 patent/US20150191445A1/en not_active Abandoned
- 2012-11-26 BR BR112014012582A patent/BR112014012582A2/pt not_active IP Right Cessation
- 2012-11-26 CN CN201280063518.9A patent/CN104159887A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150191445A1 (en) | 2015-07-09 |
| RU2014125519A (ru) | 2015-12-27 |
| CN104159887A (zh) | 2014-11-19 |
| CA2869807A1 (en) | 2013-05-30 |
| CA2869807C (en) | 2021-03-09 |
| JP2015504432A (ja) | 2015-02-12 |
| EP2784061A4 (en) | 2015-05-27 |
| KR102189562B1 (ko) | 2020-12-14 |
| BRPI1107312A2 (pt) | 2016-09-20 |
| RU2664327C2 (ru) | 2018-08-16 |
| EP2784061A1 (en) | 2014-10-01 |
| EP2784061B1 (en) | 2018-11-07 |
| KR20140112489A (ko) | 2014-09-23 |
| BR112014012582A2 (pt) | 2017-06-06 |
| WO2013075199A1 (pt) | 2013-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI296524B (en) | Angiogenesis inhibitors | |
| BRPI1107312B1 (pt) | Composto de acil-hidrazona | |
| WO2014190758A1 (zh) | 苯并呋喃酮与吲哚或氮杂吲哚偶合物及其制备与应用 | |
| JP2013502381A (ja) | 置換ヒドラジド類化合物及びその応用 | |
| WO2010096395A1 (en) | Amides as kinase inhibitors | |
| WO2022005961A1 (en) | Prpk inhibitors | |
| CN102688234B (zh) | 吲哚酮衍生物作为rsk2抑制剂的合成与应用 | |
| CN111247137A (zh) | 一种嘧啶类化合物、其制备方法及其医药用途 | |
| US11427574B2 (en) | Compounds for treating Rac-GTPase mediated disorder | |
| JP2020514260A (ja) | がんの治療における使用のためのオキサゾール誘導体 | |
| JP2024509267A (ja) | リボソーム障害に関連する貧血を処置するための組成物および方法 | |
| CN106279136B (zh) | 治疗中枢神经系统退行性疾病或脑肿瘤的化合物及其应用 | |
| CN115819349B (zh) | 一种吡唑类化合物及其制备方法和应用 | |
| US12258315B2 (en) | S6K1 protein kinase inhibitors as cancer therapeutics | |
| CN114751841B (zh) | N-(3-(3-氯苯甲酰胺)苯基)-4-甲氧基-3-硝基苯甲酰胺及其制备方法与应用 | |
| CN102688232B (zh) | 异吲哚-1,3二酮衍生物作为rsk2抑制剂的合成与应用 | |
| CN110256346A (zh) | 具有brd4蛋白抑制作用的菲啶酮类化合物及制备方法和应用 | |
| CN112250672B (zh) | 一种核苷碱基衍生物及其制备方法和应用 | |
| CN120987919A (zh) | 一种喹唑啉衍生物及其制备方法和应用 | |
| CN102690238A (zh) | 巴比妥酸衍生物作为rsk2抑制剂的合成与应用 | |
| CN120987918A (zh) | 一种嘧啶衍生物及其制备方法和应用 | |
| IT202100022682A1 (it) | Derivati pirimidinici e loro uso nel trattamento di tumori | |
| HK40019956A (en) | Pyrimidine compound, preparation method therefor and medical use thereof | |
| EP3740208A1 (en) | Compounds for treating rac-gtpase mediated disorder | |
| CN102688233A (zh) | 苯并三氮唑衍生物做为rsk2抑制剂的合成及应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25C | Requirement related to requested transfer of rights |
Owner name: UNIVERSIDADE FEDERAL DE SANTA CATARINA (BR/SC) Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 15130000910 DE 22/03/2013, E NECESSARIO APRESENTAR DOCUMENTO QUE COMPROVE QUE O REPRESENTANTE DA CEDENTE TEM PODERES PARA REALIZAR TAL ATO E O DOCUMENTO DE CESSAO DEVE TER AS FIRMAS RECONHECIDAS DO CEDENTE E DO CESSIONARIO. |
|
| B03A | Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette] | ||
| B25B | Requested transfer of rights rejected |
Owner name: UNIVERSIDADE FEDERAL DE SANTA CATARINA (BR/SC) Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 15130000910 DE 28/03/2013, POR AUSENCIA DE CUMPRIMENTO DA EXIGENCIA PUBLICADA NA RPI NO 2359, DE 22/03/2016. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: UNIVERSIDADE FEDERAL DE SANTA CATARINA (BR/SC) ; CENTRO INFANTIL DE INVESTIGACOES HEMATOLOGICAS DR. DOMINGOS A. BOLDRINI (BR/SP) |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/11/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
| B24D | Patent annual fee: restoration after fee payment |